WORCESTER, Mass., March 31, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that the company's branch office located in the Dubai Healthcare City Center hosted a seminar at NMC Specialty Hospital, Abu Dhabi. The purpose of the meeting was to introduce Generex Oral-lyn to endocrinologists, general physicians and key hospital staff employed by the NMC Specialty Hospital, Abu Dhabi which is one of the hospitals under the umbrella of NMC Hospitals (www.nmc.ae). This particular hospital spreads over 4 buildings and treats approximately 2,000 patients daily.
Generex was represented by Mr. Leo Ohanian, the General Manager of the company's branch office in Dubai, and Professor Paolo Pozzilli of University Campus Bio Medico, Rome, Italy and a clinician who has conducted studies on Generex Oral-lyn.
There are a total of 8 hospitals and medical centers under the NMC umbrella and throughout the Emirates including:
NMC Specialty Hospital, Abu Dhabi NMC Hospital, Dubai NMC Specialty Hospital, Dubai New Medical Centre, Sharjah New National Medical Centre, Mussafah National Hospital, Abu Dhabi NMC Family Clinic, Dubai NMC Specialty Hospital, Al Ain
NMC provides a wide and comprehensive range of healthcare services with a team of over 375 dedicated medical specialists in various disciplines.
"We are pleased to have had the opportunity to present at one of the NMC group of hospitals," said Mr. Ohanian. "It is an excellent venue to expose Generex Oral-lyn in the Middle East region as NMC is renowned for its commitment to using the latest technological developments in the field of healthcare."
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.